The new national statistics on bone marrow transplants were recently released on the National Marrow Donor Program website and the team from Smilow Cancer Hospital/Yale Cancer Center has once again achieved remarkable results.
Of the 157 transplant centers included in the center-specific statistics; Yale was one of 11 centers that had 1-yr survival statistics that were better than 2 standard deviations above predicted.
The predicted one-year survival for our patients was 63% and the actual survival was 73%.
Congratulations to Dennis Cooper and the entire Transplant team!
Bonnie Gould Rothberg, MD, PhD, MPH Joins Medical Oncology
Bonnie Gould Rothberg, MD, PhD, MPH will join the Yale Cancer Center faculty on July 15 as an Assistant Professor of Medical Oncology.
She will focus her efforts on our translational research goals, specifically in cancer epidemiology and tumor banking, under the mentorship of Dr. Roy Herbst, Chief of Medical Oncology.
Dr. Gould Rothberg is currently an associate research scientist in the laboratory of Dr. David Rimm in the department of pathology and will continue to work with Dr. Rimm on our DNA sequencing efforts.
She is the principal investigator on an NIH funded grant to study prognostic markers in metastatic melanoma.
Prior to coming to Yale, Dr. Gould Rothberg served as the Director of Clinical Development for the Rothberg Institute for Childhood Diseases and Group Leader for Medical Affairs at CuraGen Corporation
Dr. Gould Rothberg received her doctorate degree in Epidemiology from the Yale Graduate School of Arts and Sciences and both her medical degree and master's degree in public health from Yale School of Medicine.
Research in the News
False Negative Tests in Breast Cancer May Lead to Wrong Drug Choice
A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.
A woman diagnosed with breast cancer can be tested by immunohistochemistry (IHC), a process that detects the presence of specific proteins in cancer tissue. Those who test positive for ER are prescribed an endocrine therapy, like Tamoxifen, Letrazol or a similar drug. The 10-20% of cancer patients who are incorrectly classified as ER negative may be treated with less effective therapies.
Yale Researchers Design a Better Way to Discover Drug Candidates
Yale researchers have devised a novel way to trick cells into getting rid of problematic proteins, a method that could help pharmaceutical companies quickly identify promising targets for new drugs.
"Our new approach offers great potential in overcoming a key stumbling block in drug development today: the validation of drug target proteins in living organisms," said Craig Crews, the Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology, professor of chemistry and pharmacology, member of Yale Cancer Center, and senior author of the study.
Learn More >>
Julie Boyer has accepted a new position at Yale Cancer Center as Associate Director for Translational Research Administration working with Dr. Roy Herbst.
Prior to joining the cancer center, Julie was an assistant director of development for science and engineering at Yale.
In her new role, she will facilitate the transition of promising basic research discoveries into clinical studies at Yale Cancer Center.
Dr. Michelle Sowden recently completed the breast surgery fellowship at Yale and has received an ASCO Breast Merit Award for her work submitted to the ASCO Breast Symposium on September 8-10.
Sowden M, Sanft TB, Chagpar AB. "Who provides ongoing care to breast cancer survivors and does it make a difference?"
Ruth McCorkle was awarded funding to advance research on cancers in women through the NCI Women's Health Activities Committee to support her project, Testing the Feasibility of a Nurse Patient Navigation Intervention in Lung Cancer.
Dr. Lieping Chen presented the closing plenary lecture at the XXXVI Congress of the Spanish Society of Immunology in Pamplona, Spain on June 11th. His presentation reviewed his research showing that experimental treatments aimed at manipulating the molecules that promote the immune response against cancer can eliminate multiple mouse tumor models.
Funding and Award Opportunities
Lymphoma Research Foundation Two-Year Postdoctoral Fellowships
The LRF Fellowship provides salary support in the amount of $45,000 for the first year and $50,000 for the second year. Additionally, $5,000 per year is allotted for the research project. This makes for a total of $105,000 over two years. This Grant does not provide for institutional overhead.
The Komen Investigator-Initiated Research (IIR) Grant
Investigator-Initiated Research (IIR) Grants seek to stimulate exploration of new ideas and novel approaches in breast cancer research and clinical practice that have significant potential to lead to reductions in breast cancer incidence and/or mortality within the next decade.
Career Catalyst Research (CCR) Grants are intended to foster increased research independence of promising breast cancer researchers who are in the early stages of their faculty careers. These Grants provide support for research projects that have significant potential to advance our understanding of breast cancer and lead to reductions in breast cancer incidence and/or mortality within the next decade.
Department of Defense Visionary Postdoctoral Fellowship Award
*Research must be in one or more of the FY11 PRCRP Topic Areas
*Supports postdoctoral fellows training in the laboratory of early career investigators (mentor) with expertise in one or more of the FY11 PRCRP Topic Areas
*Supports postdoctoral training to include a budget option for research supplies
*Applications must not address breast, prostate, lung (excluding Mesothelioma), and ovarian cancer research
*Preliminary data not required
*Clinical trials will not be supported
Prostate Cancer Foundation Young Investigator Awards
The Prostate Cancer Foundation champions human capital investment to fast-forward solutions to prostate cancer. We are pleased to announce a new round of funding for Prostate Cancer Researchers. Consistent with our goal to end death and suffering from prostate cancer, we would like to focus efforts on developing another gifted cohort of human capital in prostate cancer research. Highly innovative basic science programs will be carefully considered, but priority will be given to "bench to bedside" translational research proposals with the potential to deliver near term benefit to patients.
Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research
OBJECTIVES: The sponsor provides an award to recognize outstanding achievements in clinical cancer research.
ELIGIBILITY: Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government. The award will be presented to an individual investigator. Institutions or organizations are not eligible for the award.
FUNDING: The winner of the 17th Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research will give a 50-minute lecture during the AACR 103rd Annual Meeting 2012, receive an honorarium of $10,000, and be given support for the winner and a guest to attend the Annual Meeting.
UALC aims to jumpstart new projects leading to improved treatments and a cure for lung cancer, including
non-small cell and small cell lung cancer
Proposals do not require large amounts of preliminary data, but must have a clear hypothesis and research plan to be completed within the two-year grant term.
This funding is intended primarily as seed money for promising and potentially transformative new projects, rather than funding well-developed clinical projects that already receive considerable support.
However, high risk/high reward add-on studies leveraging larger ongoing projects, or pre-existing data-sets, clinical samples, etc. are of interest.